Can a Psychiatrist Prescribe Weight Loss Medication in NC?

Can a psychiatrist prescribe weight loss medication? Yes.

For the mood side of the question, see can losing weight improve depression.

The more useful question is what a psychiatrist brings to it. Weight and mood share biology. They move together, they worsen together, and the medications that treat one often reach the other. Managing them in the same place treats the whole system instead of a single number on a scale.

If you’re weighing the options, I compare semaglutide, tirzepatide, and retatrutide side by side.

Where Weight and Mood Meet

Obesity and depression travel together, and the relationship runs both ways. A meta-analysis of longitudinal studies found that obesity raises the risk of later depression, and depression raises the risk of later obesity (Luppino, 2010). Each feeds the other.

These medications also sit at the center of a wider shift I describe in metabolic psychiatry.

One thread connecting them is inflammation. Fat tissue, especially visceral fat, is metabolically active and releases inflammatory signaling molecules. A growing body of work places inflammation among the drivers of depression in at least a subset of patients (Miller and Raison, 2016). The low-grade inflammation that accompanies obesity overlaps with the biology of low mood.

The clinical implication is worth sitting with. For some patients, treating obesity may do more than change a number on the scale. It may ease part of what drives the depression underneath. The evidence is still developing and weight loss is not an antidepressant, but the biology ties the two together closely enough that treating them in one place makes sense.

The GLP-1 Medications: Semaglutide and Tirzepatide

The medications driving most of these questions are GLP-1 receptor agonists. Semaglutide is the active ingredient in Wegovy and Ozempic. Tirzepatide, which acts on both GLP-1 and GIP receptors, is the active ingredient in Zepbound and Mounjaro.

Beyond weight, the same medications may curb drinking, which I cover in GLP-1 and alcohol.

The FDA approved Wegovy (semaglutide) for chronic weight management in adults with obesity, defined as a body mass index of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition like high blood pressure or type 2 diabetes. Zepbound (tirzepatide) carries a similar indication. In 2024 the FDA also approved semaglutide to reduce the risk of major cardiovascular events in adults with established heart disease and obesity, based on the SELECT trial, which is a meaningful expansion of what these drugs are understood to do.

They work by acting on appetite and reward pathways, slowing gastric emptying, and reducing the drive to eat. That mechanism runs through the brain, which is one reason a psychiatrist pays attention to them.

Weight Loss Inside an Integrated Plan

A GLP-1 isn’t only a metabolic drug. It acts on appetite, reward, and impulse, the same circuits psychiatry works with every day. That overlap is the reason weight medication fits naturally inside psychiatric care, alongside everything else being treated. For the deeper science on how these drugs touch mood and reward, see our piece on GLP-1 medications and mental health.

A few places it matters:

Medication fit. Antidepressants differ in how they affect weight. Mirtazapine and some SSRIs tend to increase appetite; bupropion tends to be weight-neutral or weight-reducing. When one clinician manages both the antidepressant and the GLP-1, the two are chosen and adjusted with each other in mind. If you’ve seen weight change on an antidepressant, our guide to antidepressant discontinuation covers related ground.

Eating behavior. GLP-1s reduce the reward value of food, and sometimes of alcohol. For someone with a history of disordered eating, that effect deserves attention from a clinician who knows the history and can read it in context.

The whole picture. Sleep, stress, mood, and metabolism all influence weight. A plan that already tracks those has more to work with than one focused on the medication alone. Where another clinician is involved, the work is collaborative.

The Suicidality Question and What the Research Shows

Any medication that acts on the brain invites a fair question about mood and suicide risk, and GLP-1s have drawn that question. The picture is mixed and still being sorted out.

Reports of suicidal thoughts in some patients prompted regulators to look closely. The FDA’s preliminary evaluation in January 2024 did not find evidence that these medicines cause suicidal thoughts or actions, and in January 2026 the agency requested removal of the suicidal-behavior warning from GLP-1 labeling. A large real-world cohort published in Nature Medicine found no increased risk of suicidal ideation with semaglutide. Other analyses, including a disproportionality study of a global safety database, have reported a possible signal that has not been shown to be causal.

So the weight of current evidence leans reassuring, while some uncertainty remains. What’s reasonable in that situation is straightforward: track mood while on the medication. A clinician who monitors mood as a matter of routine is well-suited to do that.

How Weight Loss Medication Is Started and Monitored in NC

Baghel Psychiatry treats weight loss medication as a managed treatment with monitoring built in. The shape of it, in broad terms:

It starts with an evaluation. Height, weight, BMI, medical history, current medications, and a look at whether a GLP-1 is the right tool. Some patients are better served by first addressing an antidepressant that’s driving weight, or a sleep or mood problem underneath the eating pattern.

If a GLP-1 is appropriate, dosing starts low and increases gradually to manage the gastrointestinal side effects that come with these drugs. Nausea, reflux, and constipation are common early on, and a measured titration schedule keeps most of them tolerable. The medications carry a boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, which is part of why the workup matters. Monitoring covers weight, tolerance, and mood, with the medication adjusted to the patient and the dose matched to response. The practice works with 503A compounding pharmacies where appropriate and bills medications separately from the monthly membership.

All of it happens by telehealth across North Carolina, inside a single plan that already accounts for whatever else is being treated. Our medical weight loss program for North Carolina lays out what’s included, and the cash-pay model is explained in full.

Frequently Asked Questions

Can any psychiatrist prescribe weight loss medication, or only some?

Yes. Prescribing GLP-1 medications is within a psychiatrist’s scope as a physician. Whether a given psychiatrist offers it is a practice decision. Baghel Psychiatry offers medical weight loss as a stated service for North Carolina patients.

Do I need a psychiatric diagnosis to get weight loss medication here?

No. Weight management is its own clinical indication based on BMI and health history. The value of seeing a psychiatrist for it is the attention to mood, appetite, and medication interactions, which matters most when those threads are already in play.

Is this covered by insurance?

The practice is cash-pay. Medications are billed separately from the monthly membership. GLP-1 insurance coverage varies widely and often excludes weight-management indications, which is part of why a transparent cash model can be simpler.

Can treating weight actually help my depression?

It may, for some patients. Obesity and depression are biologically linked, partly through inflammation, and easing one can ease the other. Weight loss is not an antidepressant, and the evidence is still developing, but treating the two together makes biological sense.

How fast will I lose weight?

That varies by person, medication, and dose, and no responsible prescriber promises a number. The clinical goal is steady, tolerable progress, with the dose matched to you and the timeline set by how you respond.

Can a psychiatrist prescribe Wegovy or Zepbound?

Yes. Both are FDA-approved for chronic weight management, and a psychiatrist is a fully licensed physician. At Baghel Psychiatry, Wegovy and Zepbound are prescribed inside the same plan as your psychiatric care.

Can a psychiatrist prescribe Ozempic or Mounjaro for weight loss?

Yes, though it’s off-label. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound contain the same active ingredients (semaglutide and tirzepatide) and carry the weight-management indication, so they’re usually the cleaner route when weight is the goal.

How does retatrutide compare with Wegovy and Zepbound?

Retatrutide is an investigational Eli Lilly drug that acts on three receptors: GLP-1, GIP, and glucagon. In its phase 2 trial, the 12 mg dose produced an average 24.2% weight reduction at 48 weeks. Lilly’s phase 3 TRIUMPH-1 results, announced in June 2026, reported an average 28.3% loss over 80 weeks. For scale, semaglutide averaged 14.9% at 68 weeks in STEP 1 and tirzepatide 20.9% at 72 weeks in SURMOUNT-1. The trials differ in length and design, so the numbers are a rough guide. Retatrutide remains unapproved, and I don’t prescribe it.

Can I get retatrutide from a compounding pharmacy or an online seller?

No. Retatrutide has no FDA approval and no legal prescription pathway, so anything sold today as retatrutide is an unregulated research chemical with no verification of dose, purity, or sterility. If the FDA approves it, that changes. Until then, Wegovy and Zepbound are the approved options.

This article is for educational purposes and is not medical advice. It does not establish a physician-patient relationship. GLP-1 medications carry risks and are not appropriate for everyone. Decisions about weight loss medication should be made with a licensed clinician who has evaluated your history. If you are experiencing thoughts of self-harm, call or text 988 to reach the Suicide and Crisis Lifeline.

References

1. Luppino FS, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Archives of General Psychiatry. 2010;67(3):220-229. PMID 20194822. pubmed.ncbi.nlm.nih.gov/20194822
2. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature Reviews Immunology. 2016;16(1):22-34. PMID 26711676. pubmed.ncbi.nlm.nih.gov/26711676
3. FDA. Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonists. January 11, 2024. fda.gov
4. FDA. FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonist Medications. January 13, 2026. fda.gov
5. FDA. Wegovy (semaglutide) prescribing information, 2025. accessdata.fda.gov
6. FDA. FDA Approves New Medication for Chronic Weight Management (Zepbound / tirzepatide). fda.gov
7. Wang W, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024;30(1):168-176. PMID 38182782. pubmed.ncbi.nlm.nih.gov/38182782
8. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232. PMID 37952131. pubmed.ncbi.nlm.nih.gov/37952131
9. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. New England Journal of Medicine. 2023;389(6). PMID 37366315. pubmed.ncbi.nlm.nih.gov/37366315
10. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3). PMID 35658024. pubmed.ncbi.nlm.nih.gov/35658024
11. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. PMID 33567185. pubmed.ncbi.nlm.nih.gov/33567185
12. Eli Lilly. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, 2026. investor.lilly.com